Loading...
•
Dec 31, 2021
Celldex Q4 2021 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
Key Takeaways
Celldex Therapeutics reported fourth-quarter financial results, with total revenue of $0.3 million and a net loss of $20.1 million, or ($0.43) per share. The company's cash, cash equivalents, and marketable securities totaled $408.3 million as of December 31, 2021, and they anticipate sufficient funds to support operations through 2025.
CDX-0159 Phase 1b study demonstrated a 95% complete response rate in chronic inducible urticaria.
Raised $287 million in gross proceeds from a public offering in July 2021.
On track to initiate Phase 2 urticaria programs in the second quarter of 2022.
Cash, cash equivalents and marketable securities as of December 31, 2021 were $408.3 million.
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2021 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.